MedTrace Logo

Everolimus in Treating Patients With Stage IV Melanoma

NCT00098553 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 53

Last updated 2016-07-06

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy, such as everolimus, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Everolimus may also stop the growth of melanoma by blocking blood flow to the tumor.

PURPOSE: This phase II trial is studying how well everolimus works in treating patients with stage IV melanoma.

Conditions

  • Melanoma (Skin)

Interventions

DRUG

everolimus

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Alliance for Clinical Trials in Oncology

    lead OTHER

Principal Investigators

  • Ravi D. Rao, MD, MBBS · Mayo Clinic

  • Harold E. Windschitl, MD · Coborn Cancer Center

  • William J. Maples, MD · Mayo Clinic

  • Michael K. Gornet, MD · Mayo Clinic

  • James N. Ingle, MD · Mayo Clinic

  • Edward T. Creagan, MD · Mayo Clinic

  • Judith S. Kaur, MD · Mayo Clinic

  • Barbara A. Pockaj, MD · Mayo Clinic Hospital

  • Evanthia Galanis, MD · Mayo Clinic

  • Charles L. Loprinzi, MD · Mayo Clinic

  • Henry C. Pitot, MD · Mayo Clinic

  • Lori A. Erickson, MD · Mayo Clinic

  • Val J. Lowe, MD · Mayo Clinic

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-04-30
Primary Completion
2007-07-31
Completion
2010-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00098553 on ClinicalTrials.gov